Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Table 1 The baseline characteristics of the patients

Case No	Gender	Before TKI treatment			TKI treatment time (month)	After TKI treatment
Case No	Gender	Tumor Stage UICC	Tumor Stage TNM	EGFR mutation subtype	TKI treatment time (month)	Tumor Stage UICC	Tumor Stage TNM	EGFR mutation subtype
01	Female	IV	cT2aN2M1	L858R	12	IIIA	pT2N2M0	T790 M/L858R
02	Female	IV	cT2aN2M1	19-Del	9	IB	pT2N0M0	T790 M
03	Female	IV	cT4N2M1	19-Del	7	IIIA	pT2N2M0	19-Del
04	Male	IV	cT1cN2M1	L858R	7	IA	pT1bN0M0	L858R
05	Male	IIIB	cT4N2M0	19-Del	3	IA	pT1N0M0	19-Del
06	Male	IIIC	cT3N3M0	19-Del	3	IB	pT2aN0M0	19-Del
07	Female	IIIA	cT2bN3M0	19-Del	2	IA	pT1N0M0	19-Del
08	Female	IIIB	cT3N3M0	19-Del	5	IB	pT2bN1M0	19-Del
09	Male	IIIA	cT2aN2M0	19-Del	3	IB	pT2aN0M0	19-Del
10	Male	IIIB	cT4N2M0	19-Del	3	IA	pT1N0M0	19-Del
11	Male	IB	pT2BN0M0	19-Del	N
12	Male	IIIA	pT2N2M0	19-Del	N
13	Female	IIB	pT3N0M0	L858R	N

Case number 01–07 patients after biopsy and EGFR mutational testing verified the presence of EGFR-TKI-sensitive mutations, under treatment with TKIs. Finally confirmed cTNM downstaging to IIIA at least and then the patients underwent initial surgery. Those patients harbor paired tissue of pre- and post- treatment
Case number 07–10 patients were initially subjected to EGFR mutational testing using peripheral blood, tissue samples were collected only after TKI treatment. Case number 11–13 underwent initial surgery at the Department of Thoracic Surgery during the same period and were confirmed to possess sensitive EGFR mutations

ISSN: 1756-9966